More Alzheimer's Pain As J&J Pulls Plug On BACE Inhibitor

 
• By Kevin Grogan

J&J's Janssen unit is ending development of atabecestat after serious elevations of liver enzymes were seen in some patients who received the drug, increasing doubts about the BACE inhibitor mechanism as an appropriate target.

Rock slide
Still blocked: No BACE breakthrough for J&J

More from Clinical Trials

More from R&D